Performance of the EarlyCDT Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort
Lung Cancer — Borg M, Wen SWC, Nederby L, et al. | June 11, 2021
Researchers tested the performance of the seven-panel TAA (tumor-related autoantibodies) assay (EarlyCDT Lung), mainly its ability to detect cancer, in a cohort of patients (n = 246) referred from their general practitioner on suspicion of lung cancer. They found an overall sensitivity of 33 % for lung cancer and 31 % for primary lung cancer and lung metastases combined, in the cohort. In age groups, the observed sensitivity was 11 % (60 years or below), 31 % (61−75 years) and 55 % (>75 years). A sensitivity of 33 % and 44 % was revealed in patients with at least 10 tobacco pack years and in those with at least 50 tobacco pack years, respectively. In stage I-II lung cancer patients and in those with stage III-IV, the assay offered a sensitivity of 21 % and 40 %, respectively. Findings revealed that the performance displayed by the EarlyCDT Lung test was the best in elderly, late stage lung cancer patients with a heavy smoking history. In the light of these results, it was inferred that EarlyCDT Lung test lacks sufficient sensitivity to be used as part of inclusion criteria in a low-dose computed tomography program for lung cancer detection.
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.